Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review

Research output: Contribution to journalReviewResearchpeer-review

  1. Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 'Barrier dysfunction in Atopic newBorns studY' (BABY): protocol of a Danish prospective birth cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cancer risk in patients with psoriasis: should we be paying more attention?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Psoriasis is a prevalent chronic inflammatory disease. The inflammatory response is driven by T cells and mediated by multiple cytokines such as tumor necrosis factor and the interleukins IL-17 and IL-23. Moderate-to-severe psoriasis is treated systemically, using either biologics or conventional treatments with small-molecule drugs. The newer biologics are very effective and well tolerated, but not all patients respond to treatment with biologics, so there is a need for new treatment options for psoriasis. Janus kinase (JAK) inhibitors are a new drug class that may be of use in this respect. These inhibitors are already on the market for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. They block the intracellular signal pathway mediated by JAK and signal transducer and activator of transcription (STAT) proteins, thereby inhibiting gene transcription of proinflammatory cytokines. JAK inhibitors are currently being tested as potential treatments for psoriasis. They have shown clinical efficacy as measured by the Psoriasis Area and Severity Index 75 response in both phase 2 and 3 trials, and appear to be well tolerated overall. This review provides an overview of the mechanisms underlying the actions of JAK inhibitors in psoriasis, together with the results of clinical trials testing their efficacies when used to treat the disease.

Original languageEnglish
JournalDermatology and therapy
Volume10
Issue number1
Pages (from-to)29-42
Number of pages14
ISSN2193-8210
DOIs
Publication statusPublished - 1 Feb 2020

    Research areas

  • Efficacy, JAK inhibitors, JAK-STAT signaling pathway, Psoriasis, Tofacitinib, Treatment, TYK2 inhibitors

ID: 59447924